Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas

15 Aug 2024

Abstract excerpt

Although chimeric antigen receptor (CAR) T cell therapy has revolutionized type B cancer treatment, efficacy remains limited in various lymphomas and solid tumors. Reinforcing conventional CAR-T cells to release cytokines can improve their efficacy but also increase safety concerns. Several strategies have been developed to regulate their secretion using minimal promoters that are controlled by chimeric proteins...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39640015
DOI: 10.1016/j.omtn.2024.102308

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomasPMID 39640015Read ↗

<i>First-in-class</i> Transactivator-Free, Doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B-cell lymphomasSemantic proximity Read ↗

Synthetic promoters to induce immune-effectors into the tumor microenvironmentSemantic proximity Read ↗

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen ReceptorSemantic proximity Read ↗

CAR-T design: Elements and their synergistic functionSemantic proximity Read ↗

Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cellsSemantic proximity Read ↗

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cellsSemantic proximity Read ↗

CAR T Cells Secreting IL18 Augment Antitumor Immunity and Increase T Cell Proliferation and CostimulationSemantic proximity Read ↗

Application and Design of Switches Used in CARSemantic proximity Read ↗

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read ↗

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.